284 related articles for article (PubMed ID: 32861131)
1. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
Armocida D; Frati A; Salvati M; Santoro A; Pesce A
Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
[TBL] [Abstract][Full Text] [Related]
2. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
3. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
4. Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
Tini P; Yavoroska M; Mazzei MA; Miracco C; Pirtoli L; Tomaciello M; Marampon F; Minniti G
J Neurooncol; 2023 Jun; 163(2):339-344. PubMed ID: 37227648
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
6. Impact of Multifocality and Molecular Markers on Survival of Glioblastoma.
Ahmadipour Y; Jabbarli R; Gembruch O; Pierscianek D; Darkwah Oppong M; Dammann P; Wrede K; Özkan N; Müller O; Sure U; El Hindy N
World Neurosurg; 2019 Feb; 122():e461-e466. PubMed ID: 30347300
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of STAT3 gene expression in patients with glioblastoma tumors: a study from Western India.
Trivedi T; Panchal K; Bhalala N; Trivedi P
J Egypt Natl Canc Inst; 2022 Jul; 34(1):30. PubMed ID: 35844028
[TBL] [Abstract][Full Text] [Related]
8. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors.
Paldor I; Pearce FC; Drummond KJ; Kaye AH
J Clin Neurosci; 2016 Dec; 34():128-132. PubMed ID: 27593971
[TBL] [Abstract][Full Text] [Related]
9. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
11. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
[TBL] [Abstract][Full Text] [Related]
12. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
13. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
14. Correlation of Ki-67 Index with Volumetric Segmentation and its Value as a Prognostic Marker in Glioblastoma.
Henker C; Kriesen T; Schneider B; Glass Ä; Scherer M; Langner S; Erbersdobler A; Piek J
World Neurosurg; 2019 May; 125():e1093-e1103. PubMed ID: 30790732
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Prognosis of High-Grade gliomas in the View of New Immunohistochemistry Markers and 2016 WHO Classification.
Dolen D; Ahmadov T; Dolas I; Unal TC; Aydoseli A; Ozturk M; Sabanci PA; Aras Y; Bilgic MB; Sencer A
Turk Neurosurg; 2022; 32(3):500-507. PubMed ID: 35615769
[TBL] [Abstract][Full Text] [Related]
16. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
[TBL] [Abstract][Full Text] [Related]
17. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
19. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
20. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
Wu H; Tong H; Du X; Guo H; Ma Q; Zhang Y; Zhou X; Liu H; Wang S; Fang J; Zhang W
Eur Radiol; 2020 Jun; 30(6):3254-3265. PubMed ID: 32078014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]